Highline Capital Management’s UroGen Pharma URGN Stock Holding History

Highline Capital Management’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-222,776	Closed	-$3.97M	–	31
2020 Q1	$3.97M	Sell	222,776 -626,702	-74%	-$16.9M	0.97%	21
2019 Q4	$28.3M	Sell	849,478 -27,642	-3%	-$754K	4.49%	14
2019 Q3	$20.9M	Sell	877,120 -136,958	-14%	-$4.48M	3.05%	15
2019 Q2	$36.4M	Buy	1,014,078 +27,200	+3%	+$1M	2.67%	19
2019 Q1	$36.5M	Buy	986,878 +525,200	+114%	+$22M	2.29%	22
2018 Q4	$19.9M	Buy	461,678 +129,778	+39%	+$5.83M	1.33%	24
2018 Q3	$15.7M	Hold	331,900	–	–	0.73%	27
2018 Q2	$16.5M	Sell	331,900 -44,923	-12%	-$2.61M	0.55%	36
2018 Q1	$18.7M	Sell	376,823 -23,077	-6%	-$1.16M	0.64%	30
2017 Q4	$14.9M	Sell	399,900 -10,100	-2%	-$360K	0.49%	31
2017 Q3	$12.9M	Sell	410,000 -15,300	-4%	-$338K	0.37%	36
2017 Q2	$7.68M	Buy	+425,300	New	+$7.38M	0.24%	35

Other funds holding URGN

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HCM

Horton Capital Management Philadelphia, Pennsylvania $44.9M AUM 24.87% 1-Year Est. Return

Highline Capital Management's URGN Position: Q2 2020 in Review

Highline Capital Management sold out of UroGen Pharma (URGN) in Q2 2020, closing a stake of 222,776 shares — an estimated $3.97M sold.

Highline Capital Management first reported a position in URGN in Q2 2017 and held it in 12 quarters. The position peaked at $36.5M in Q1 2019. 84 funds tracked by Wall St. Rank hold URGN as of Q2 2020.

Highline Capital Management reported no remaining UroGen Pharma position as of Q2 2020 after selling out during the quarter.
Highline Capital Management sold 222,776 UroGen Pharma shares in Q2 2020, an estimated $3.97M.
Highline Capital Management first reported a position in UroGen Pharma in Q2 2017 and held it in 12 quarters.
Highline Capital Management's UroGen Pharma position peaked at $36.5M in Q1 2019.
84 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2020.

Based on Highline Capital Management's 13F filing for Q2 2020, filed 14 Aug 2020.